• News

"Mount Sinai Institutes Join $215 Million Partnership To Increase Patients’ Immunotherapy Success"

  • The ASCO Post
  • NEW YORK, NY
  • (December 10, 2017)

The Tisch Cancer Institute and the Precision Immunology Institute at Mount Sinai Health System are part of a $215 million public-private Cancer Moonshot research collaboration launched by the National Institutes of Health and 11 leading pharmaceutical companies.  This collaboration will dive deep into tumors and the immune system’s interactions with them at the cellular and molecular levels to identify biomarkers present in malignant and healthy tissues to determine how to make immunotherapies work for more patients. “The Tisch Cancer Institute is committed to conduct innovative profiling of the immune system to determine the best approaches for therapy and prevention,” said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute, Ward-Coleman Chair in Cancer Research, and Chair of the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. “This groundbreaking Cancer Moonshot collaboration between industry, government, medicine, and academia is a great new initiative toward bringing the most effective and individualized treatments to more patients sooner,” he added.

- Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute at Mount Sinai, Professor, Chair, Oncological Sciences, Icahn School of Medicine at Mount Sinai

Learn more

Related Articles
Doctor adjusting microscope
Building exterior
Doctor adjusting microscope
Building exterior
Doctor adjusting microscope
Parekh
Doctor adjusting microscope
Doctor adjusting microscope
Myeloma
Researcher using microscope
Treatment resistance